Northwind Pharmaceuticals

New drugs approved for 2014-A Recap of What We’ve Seen This Year

New-drugs-approved-for-2014-A-Recap-of-What-We’ve-Seen-This-YearAs we look back on 2014, it’s been a big year when it comes to newly approved medications. The FDA has been busy, with a long list of both generic and brand name pharmaceuticals getting their stamp of approval. Let’s talk highlights.

  • Cardiology and Vascular Diseases – Zontivity:  For the reduction of thrombotic cardiovascular events.
  • Family Medicine – Arnuity Ellipta: For the treatment of asthma.
  • Gastroenterology – Cyramza: For the treatment of gastric cancer.
  • Genetic Disease – Alprolix:  For the treatment of hemophilia B.
  • Immunology – Triumeq: For the treatment of HIV-1.
  • Musculoskeletal – Vimizim: For the treatment of Mucopolysaccharidosis type IVA.
  • Nephrology – Harvoni: For the treatment of hepatitis C.
  • Neurology – Belsomra: For the treatment of insomnia.
  • Nutrition and Weight Loss – Contrave: For chronic weight management.

To see a full list of all 2014 FDA approved medications click here.

Available pharmaceuticals change from year to year, with more being added all the time. When you partner with Northwind Pharmaceuticals, you have access to top industry information on the best medications to prescribe to your patients. When drugs become available, we’ll track them down and provide you with a competitive price supported by our responsive customer service. Contact us today to see how our solutions can lead to greater success in 2015.

Schedule a free claims analysis now.

Let’s Talk now

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading

Letter From a Pharmacist – On Pharmacy Closures

Phillip Berry | Oct 25th, 2024
Pharmacists have a time-honored role as an integral contributor to the delivery of health care. From the earliest apothecaries to the retail stores of today, community pharmacists have provided guidance about health, wellness and medication therapy. Their expertise ranges from preventive care to the most advanced medications used in the treatment of complex disease.  Despite … more »

continue reading